US Exchange Filings

Exicure Proposes NeuroQ Acquisition to Advance Parkinson’s Smart-Glasses Technology

Exicure is expanding beyond biotechnology into medical devices aimed at Parkinson’s disease, through a proposed investment in NeuroQ Biologics and its X-CUE smart-glasses technology. The agreement, signed November 19, sets out a possible equity acquisition and development funding, but key transaction terms remain to be negotiated.

X-CUE uses augmented-reality visual cues intended to help people with Parkinson’s manage freezing-of-gait episodes, which can interrupt movement and daily activities. The latest version has completed product development and is being prepared for clinical evaluation; commercial use would still depend on clinical results and regulatory approvals.

Key details

  • Proposed ownership: Exicure intends to acquire between 20% and 100% of NeuroQ. The planned exchange is primarily Exicure common shares for NeuroQ shares held by Laonz.
  • Terms are not final: The ownership percentage, share-exchange ratio and other transaction terms will be set in later written agreements. The transaction is subject to corporate and regulatory approvals and Nasdaq requirements.
  • Potential funding: After the proposed share acquisition is completed, Exicure intends to provide up to $500,000 for X-CUE’s clinical evaluation, regulatory work, manufacturing preparation and commercialization efforts. The funding remains subject to approvals, available funds and definitive arrangements.
  • Business and technology transferred: Laonz has completed the transfer of the X-CUE business—including related intellectual property, technology, assets and business rights—to NeuroQ.
  • Who leads development: NeuroQ is expected to lead X-CUE’s continued development, clinical evaluation, regulatory approval process and commercialization, with strategic support from Exicure.
  • Clinical timing: The company says the latest, third-revised version is ready for planned clinical trials, with an anticipated evaluation period of about six months. That is a planned timetable, not a report that trials have begun or that the device is approved.
  • Broader strategy: Exicure said its portfolio includes a clinical-stage program targeting stem-cell mobilization for multiple myeloma, sickle cell disease and cell- and gene-therapy applications. The agreement adds medical-device technologies to its strategic focus.

Implications

If completed as proposed, the deal would give Exicure an ownership interest in NeuroQ in exchange primarily for newly issued Exicure shares, which would dilute existing shareholders; the extent of any dilution cannot be determined because the exchange ratio and stake have not been finalized. The company’s potential cash contribution is capped at $500,000 under the announced plan, but remains conditional. X-CUE’s commercial prospects depend on clinical evaluation and regulatory approval, neither of which is assured.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.